ModifiedUnitedHealthcarePolicy DCP033.12

In-Office Drug Administration and Dispensing of Medications

This policy governs dental in-office parenteral drug administration, infiltration of sustained-release therapeutic drugs, and dispensing of drugs for home use in dental settings; it affects dental providers and coverage determinations under UnitedHealthcare dental benefits.

Policy Summary

PayerUnitedHealthcare

PolicyIn-Office Drug Administration and Dispensing of Medications

Policy CodePolicy DCP033.12

Change TypeOperational updates to coverage rationale and evidence sections

Effective DateJul 1, 2025

Next Review Date

Key ActionReference member-specific benefit plan documents to determine coverage and prior authorization requirements; document analgesic prescribing decisions.

SourceLink

POLICY UPDATE CHANGES

Removed example of sustained release therapeutic drug (Exparel ® ).

Updated Clinical Evidence and References sections to reflect the most current information.

4primary service categories

4+evidence summaries

D9610-D9630procedure codes referenced

63RCTs in 2021 review

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

74%trials w/ no significant pain relief

Coverage Criteria

Therapeutic Parenteral Drug Administration

Covered when used for appropriate clinical indications in dental practice:

Therapeutic parenteral administration: May be indicated to enhance healing of surgical procedures, manage post-procedure nausea and vomiting, or reduce pain and/or risk of infection; medications include antibiotics, steroids, anti-inflammatory drugs, or antiemetics.

Infiltration of Sustained-Release Therapeutic Drug

Not indicated:

Sustained-release infiltration: Infiltration of a sustained release therapeutic drug (single or multiple sites) is not indicated due to insufficient evidence of efficacy and/or safety.

Drugs or Medicaments Dispensed in the Office for Home Use

Covered when used to support post-procedure care:

Office-dispensed medications: Dispensing of drugs in the dental office for home use may be indicated to enhance healing of surgical procedures, reduce pain and/or risk of infection, and reduce caries risk; examples include oral antibiotics, oral analgesics, and topical fluoride.

Clinical evidence synthesis

Evidence summary and clinical recommendations

Evidence findings: Systematic reviews and randomized trials provide mixed results: a 2021 systematic review (63 RCTs, 6770 subjects) found liposomal bupivacaine did not result in significant pain relief in over 74% of trials and did not reduce opioid consumption in almost 86% of trials; some individual dental studies (INNOVATE, Glenn, Bultema) showed inconsistent or no superiority versus placebo or standard bupivacaine, while a randomized open-label full-arch implant trial (Iero et al., 266 mg) reported reduced cumulative pain and opioid use.

Further high-quality research recommended; AAOMS guidance supports multimodal analgesia with NSAIDs/acetaminophen first-line and considers long-acting local anesthetics among options.

Infiltration of a sustained-release therapeutic drug (single or multiple sites) is not indicated due to insufficient evidence of efficacy and/or safety.

The policy excerpt does not state any explicit coverage exclusions specific to liposomal bupivacaine (Exparel); available text summarizes clinical evidence and notes limited or mixed findings rather than listing a named exclusion.

Evidence for use of liposomal bupivacaine (Exparel) in oral and maxillofacial surgery is limited and inconsistent. Individual dental trials report mixed results: some studies (for example, Iero et al. in full-arch implant surgery) suggested reduced cumulative pain and opioid use in a specific protocol, while other dental trials (including INNOVATE and small randomized trials of third-molar extraction) did not show consistent superiority over standard bupivacaine or placebo. The policy notes further research is needed to determine any clear clinical advantage.

A 2021 systematic review (Ji et al.) pooling 63 RCTs (6,770 subjects across multiple surgical specialties, including four oral/maxillofacial surgery trials) concluded that liposomal bupivacaine did not provide significant pain relief in over 74% of trials and did not reduce opioid consumption in almost 86% of trials; the authors judged that superiority for postoperative pain control was not supported by a majority of RCTs due to low quality and high risk of bias and recommended further high-quality research.

Coding

Referenced CDT Procedure CodesCPT

D9610	Therapeutic parenteral drug, single administration.
D9612	Therapeutic parenteral drugs, two or more administrations, different medications.
D9613	Infiltration of sustained release therapeutic drug, per quadrant.
D9630	Drugs or medicaments dispensed in the office for home use.

Codes referencedmixed

No explicit CPT/HCPCS/ICD-10 codes listed in this document portion

Policy excerpt does not contain specific billing codes.

Liposomal bupivacaine dose (trial)

Dose used in reported trial266 mg

Study contextFull-arch implant surgery trial reported liposomal bupivacaine 266 mg administered at end of surgery

Comparator analgesiaAll patients also received infiltration with ≤40 mL lidocaine 2% with epinephrine and bupivacaine 0.5% periprocedurally

Provider Actions and Authorization

Documentation Required

Reference and Documentation

Reference member benefit plan documents and applicable laws to determine coverage and reimbursement. Listing a procedure code or service in this policy does not guarantee coverage or payment; benefits are subject to the member's specific plan terms and any applicable federal or state mandates. Providers should keep copies of the relevant benefit plan provisions when submitting claims and contact UnitedHealthcare if clarification is needed.

Benefit coverage is determined by the member-specific benefit plan document and applicable laws.
Listing a code in this policy does not imply coverage, reimbursement, or guarantee of payment.
Consult the member's plan documents and UnitedHealthcare provider resources for authorization and billing guidance.

Prior Authorization

Prior Authorization — Verify Before Treatment

Prior authorization may be required for certain in-office therapeutic parenteral drug administrations or for dispensing medications; providers must verify prior authorization requirements with UnitedHealthcare before performing services. When prior authorization is required, include complete clinical documentation to support medical necessity.

Background

Parenteral administration refers to any technique that bypasses the gastrointestinal tract. In dental practice this includes routes such as intramuscular (IM), intravenous (IV), intranasal (IN), submucosal (SM), subcutaneous (SC), and intraosseous (IO). Parenteral drugs in-office may be used to enhance surgical healing, manage postoperative nausea or vomiting, reduce pain, or decrease infection risk; however, sustained-release infiltrations (for example, liposomal bupivacaine) have limited and mixed evidence for benefit in oral and maxillofacial procedures.

Definitions

Parenteral — definition and routes

DefinitionParenteral administration: technique in which the drug bypasses the gastrointestinal tract

Example routesIntramuscular (IM), Intravenous (IV), Intranasal (IN), Submucosal (SM), Subcutaneous (SC), Intraosseous (IO)

Clinical noteIncludes injections and other non‑enteral routes used in dental practice for perioperative therapeutics

Liposomal bupivacaine (Exparel) — definition and evidence

DefinitionExparel (liposomal bupivacaine): a sustained‑release, long‑acting local injection that encapsulates bupivacaine in multivesicular liposomes

MechanismLiposomes gradually release bupivacaine as lipid membranes are absorbed, producing prolonged analgesia

Policy Summary

PayerUnitedHealthcare

PolicyIn-Office Drug Administration and Dispensing of Medications

Policy CodePolicy DCP033.12

Change TypeOperational updates to coverage rationale and evidence sections

Effective DateJul 1, 2025

Next Review Date

Key ActionReference member-specific benefit plan documents to determine coverage and prior authorization requirements; document analgesic prescribing decisions.

SourceLink

On This Page

Check prior authorization requirements for codes such as D9610, D9612, D9613, D9630 where applicable.
A listed code does not indicate that prior authorization is not required — always verify against the member's benefit plan and payer authorizations.

Documentation Required

Analgesic Prescribing and Documentation Expectations

When prescribing or administering analgesics (including NSAIDs, acetaminophen, and opioids), document the clinical rationale, medication name, dose, route, frequency, intended duration, and patient education provided. If opioids are prescribed, document screening for misuse, access to the state PDMP when required by law, and justification for opioid choice and duration. If deviating from AAOMS or state guidance, document the clinical justification.

Document analgesic sequencing per AAOMS: NSAIDs first-line unless contraindicated; acetaminophen if NSAIDs contraindicated; consider short-acting opioids only for breakthrough pain with lowest effective dose and shortest duration.
Record patient education on postoperative pain expectations and analgesic use.
If required by law, document access to and review of the state PDMP and any screening for substance misuse.

Denial Risk

Provider Cautionary Note

Caution: The absence of explicit prior authorization rules in this portion of the policy does not mean none apply. Always verify authorizations, billing rules, and member eligibility prior to providing services to avoid claim denials.

Verify whether procedure- or drug-specific prior authorization is required through payer portals or provider services.
Retain contemporaneous clinical records to support claims and authorizations.

Evidence noteClinical evidence in oral/maxillofacial surgery is limited and mixed; systematic reviews and RCTs show variable results and further research is needed

Liposomal bupivacaine — brief definition

Short definitionA sustained‑release formulation of bupivacaine for local infiltration to prolong postoperative analgesia

Intended effectDesigned to delay onset and reduce severity of postoperative pain as a long‑acting local anesthetic

Clinical guidanceEvidence for routine superiority over standard bupivacaine is not established; AAOMS lists long‑acting local anesthetics (including liposomal bupivacaine) among options